These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 37705378)

  • 1. Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis.
    Balakirski G; Burmann SN; Hofmann SC; Kreuter A
    J Dermatolog Treat; 2023 Dec; 34(1):2258240. PubMed ID: 37705378
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
    Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Atopic Dermatitis and Psoriasis Vulgaris: Implications for Targeted Biologic Therapy.
    Johnson MC; Bowers NL; Strowd LC
    Cutis; 2022 Feb; 109(2):110-112. PubMed ID: 35659797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review.
    Su Z; Zeng YP
    Dermatology; 2023; 239(4):646-657. PubMed ID: 37100035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.
    Simpson EL; Guttman-Yassky E; Eichenfield LF; Boguniewicz M; Bieber T; Schneider S; Guana A; Silverberg JI
    Allergy; 2023 Nov; 78(11):2875-2891. PubMed ID: 37455359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
    Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
    Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. English version of Japanese guidance for biologics in treating atopic dermatitis.
    Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
    J Dermatol; 2023 Oct; 50(10):e311-e322. PubMed ID: 37650357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.
    Parker JJ; Sugarman JL; Silverberg NB; Gonzalez ME; Ramien ML; Teng JMC; Paller AS
    Pediatr Dermatol; 2021 Nov; 38(6):1500-1505. PubMed ID: 34647354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
    Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
    J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults.
    Pezzolo E; Sechi A; Tartaglia J; Naldi L
    Expert Rev Clin Immunol; 2024 Mar; 20(3):255-266. PubMed ID: 37955186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.
    Kaufman BP; Alexis AF
    Curr Allergy Asthma Rep; 2018 Aug; 18(10):55. PubMed ID: 30171358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
    Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
    Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations.
    Butala S; Castelo-Soccio L; Seshadri R; Simpson EL; O'Shea JJ; Bieber T; Paller AS
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1361-1373. PubMed ID: 36948491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
    Wollenberg A; Howell MD; Guttman-Yassky E; Silverberg JI; Kell C; Ranade K; Moate R; van der Merwe R
    J Allergy Clin Immunol; 2019 Jan; 143(1):135-141. PubMed ID: 29906525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents.
    Ewulu AR; Prajapati S; Feldman SR
    Immunotherapy; 2023 Nov; 15(16):1341-1349. PubMed ID: 37641871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):205-221. PubMed ID: 31964499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
    Guttman-Yassky E; Kabashima K; Staumont-Salle D; Nahm WK; Pauser S; Da Rosa JC; Martel BC; Madsen DE; Røpke M; Arlert P; Steffensen L; Blauvelt A; Reich K
    Allergy; 2024 Jun; 79(6):1560-1572. PubMed ID: 38563683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.